XBRU:UCB (Belgium)
Business Description
UCB SA
NAICS : 325412
60, Allee de la Recherche, Brussels, BEL, B-1070
Compare
Compare
Traded in other countries / regions
UCB.Austria
•
UCB.Belgium
•
UNC.Germany
•
UCB.Mexico
•
0NZT.UK
•
UCBJF.USA
Description
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.33 | |||||
| Equity-to-Asset | 0.55 | |||||
| Debt-to-Equity | 0.34 | |||||
| Debt-to-EBITDA | 1.95 | |||||
| Interest Coverage | 27.3 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 2.82 | |||||
| Beneish M-Score | -2.42 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -15.4 | |||||
| 3-Year EBITDA Growth Rate | -17.2 | |||||
| 3-Year EPS without NRI Growth Rate | -13.5 | |||||
| 3-Year FCF Growth Rate | -11.7 | |||||
| 3-Year Book Growth Rate | 9.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 1.95 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 0.39 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.7 | |||||
| 9-Day RSI | 27.64 | |||||
| 14-Day RSI | 30.85 | |||||
| 6-1 Month Momentum % | -0.98 | |||||
| 12-1 Month Momentum % | -13.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.13 | |||||
| Quick Ratio | 0.83 | |||||
| Cash Ratio | 0.34 | |||||
| Days Inventory | 200.97 | |||||
| Days Sales Outstanding | 69.07 | |||||
| Days Payable | 384.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.78 | |||||
| Dividend Payout Ratio | 0.28 | |||||
| 3-Year Dividend Growth Rate | 2.5 | |||||
| Forward Dividend Yield % | 1.78 | |||||
| 5-Year Yield-on-Cost % | 2.04 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 73.09 | |||||
| Operating Margin % | 19.82 | |||||
| Net Margin % | 14.96 | |||||
| ROE % | 10.64 | |||||
| ROA % | 6.1 | |||||
| ROIC % | 8.3 | |||||
| ROC (Joel Greenblatt) % | 89.1 | |||||
| ROCE % | 9.5 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 16.04 | |||||
| Forward PE Ratio | 19.88 | |||||
| PE Ratio without NRI | 16 | |||||
| Shiller PE Ratio | 12.75 | |||||
| Price-to-Owner-Earnings | 9.95 | |||||
| PS Ratio | 2.4 | |||||
| PB Ratio | 1.55 | |||||
| Price-to-Free-Cash-Flow | 14.46 | |||||
| Price-to-Operating-Cash-Flow | 9.72 | |||||
| EV-to-EBIT | 14.13 | |||||
| EV-to-Forward-EBIT | 19.02 | |||||
| EV-to-EBITDA | 10.25 | |||||
| EV-to-Forward-EBITDA | 13.1 | |||||
| EV-to-Revenue | 2.68 | |||||
| EV-to-Forward-Revenue | 2.98 | |||||
| EV-to-FCF | 16.15 | |||||
| Price-to-Projected-FCF | 1.14 | |||||
| Price-to-Median-PS-Value | 1.53 | |||||
| Earnings Yield (Greenblatt) % | 7.08 | |||||
| Forward Rate of Return (Yacktman) % | -2.67 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 5,924 | ||
| EPS (TTM) (€) | 4.56 | ||
| Beta | 0.43 | ||
| Volatility % | 35.42 | ||
| 14-Day RSI | 30.85 | ||
| 14-Day ATR (€) | 1.887516 | ||
| 20-Day SMA (€) | 77.336 | ||
| 12-1 Month Momentum % | -13.31 | ||
| 52-Week Range (€) | 72.34 - 116.05 | ||
| Shares Outstanding (Mil) | 189.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
UCB SA Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||